Based on 16 Wall Street analysts offering 12 month price targets for Ionis Pharmaceuticals in the last 3 months. The average price target is $58.69 with a high forecast of $75.00 and a low forecast of $37.00. The average price target represents a 37.03% change from the last price of $42.83.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"33":"$33","76":"$76","43.75":"$43.8","54.5":"$54.5","65.25":"$65.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":58.69,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$58.69</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$37.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[33,43.75,54.5,65.25,76],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2023","6":"Nov<br/>2023","9":"Feb<br/>2024","12":"May<br/>2024","25":"May<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.43,45.85846153846154,48.286923076923074,50.715384615384615,53.143846153846155,55.57230769230769,58.00076923076923,60.42923076923077,62.857692307692304,65.28615384615384,67.71461538461539,70.14307692307692,72.57153846153847,{"y":75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.43,44.603846153846156,45.777692307692305,46.95153846153846,48.12538461538462,49.29923076923077,50.473076923076924,51.64692307692307,52.82076923076923,53.994615384615386,55.168461538461536,56.34230769230769,57.51615384615384,{"y":58.69,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.43,42.93538461538461,42.44076923076923,41.94615384615385,41.45153846153846,40.956923076923076,40.46230769230769,39.96769230769231,39.473076923076924,38.97846153846154,38.48384615384615,37.98923076923077,37.494615384615386,{"y":37,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":34.979,"date":1683244800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":42.025,"date":1685664000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":41.74,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.495,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.615,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.73,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.19,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.9,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.378,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.61,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.9,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.09,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.43,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$75.00

Average Price Target$58.69

Lowest Price Target$37.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

xxxxxxxxxxxxxxxxxx

Oppenheimer

xxxxxxxxxxxxx

Reiterated

04/30/24

xxxxxxxxxxxxxxxxxx

Piper Sandler

xxxxxxxxxxxxx

Assigned

04/26/24

xxxxxxxxxxxxxxxxxx

Wolfe Research

xxxxxxxxxxxxx

Upgraded

04/09/24

xxxxxxxxxxxxxxxxxx

Needham

xxxxxxxxxxxxx

Reiterated

04/09/24

xxxxxxxxxxxxxxxxxx

Wells Fargo

xxxxxxxxxxxxx

Assigned

04/08/24

xxxxxxxxxxxxxxxxxx

Stifel Nicolaus

xxxxxxxxxxxxx

Reiterated

04/08/24

xxxxxxxxxxxxxxxxxx

Bernstein

xxxxxxxxxxxxx

Reiterated

04/08/24

xxxxxxxxxxxxxxxxxx

Citi

xxxxxxxxxxxxx

Reiterated

04/08/24

xxxxxxxxxxxxxxxxxx

J.P. Morgan

xxxxxxxxxxxxx

Reiterated

04/07/24

xxxxxxxxxxxxxxxxxx

TD Cowen

xxxxxxxxxxxxx

Reiterated

03/14/24

Yale Jen

Laidlaw

$68.00

Buy

58.77%

Upside

Reiterated

03/13/24

Laidlaw reiterates Buy Rating on Ionis Pharmaceuticals (IONS)Laidlaw analyst Yale Jen reiterated a Buy rating and $68.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS).

Gena Wang

Barclays

$45.00

Hold

5.07%

Upside

Assigned

02/21/24

Barclays Remains a Hold on Ionis Pharmaceuticals (IONS)

Kostas Biliouris

BMO Capital

$67.00

Buy

56.43%

Upside

Assigned

02/21/24

Ionis Pharmaceuticals: A Strong Buy on ATTR Franchise Prospects and Financial Fortitude

Mani Foroohar

Leerink Partners

$48.00

Hold

12.07%

Upside

Assigned

02/21/24

Analysts' Opinions Are Mixed on These Healthcare Stocks: Exact Sciences (NASDAQ: EXAS), United Therapeutics (NASDAQ: UTHR) and Ionis Pharmaceuticals (NASDAQ: IONS)

Luca Issi

RBC Capital

$70.00

Buy

63.44%

Upside

Reiterated

02/21/24

RBC Capital Remains a Buy on Ionis Pharmaceuticals (IONS)

0JDI Analyst Recommendation Trends

Rating

Dec 23

Jan 24

Feb 24

Mar 24

Apr 24

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0JDI has received 26 Buy Ratings, 5 Hold Ratings, and 1 Sell Ratings. 0JDI average Analyst price target in the past 3 months is $58.69.

Each month's total comprises the sum of three months' worth of ratings.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxxxxxxxxxxxxxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

0JDI Financial Forecast

0JDI Earnings Forecast

Next quarter’s earnings estimate for 0JDI is -$1.03 with a range of -$1.38 to -$0.62. The previous quarter’s EPS was -$0.06. 0JDI beat its EPS estimate 66.67% of the time in the past 12 months, while its overall industry beat the EPS estimate 37.50% of the time in the same period. In the last calendar year 0JDI has Outperformed its overall industry.

0JDI Sales Forecast

Next quarter’s sales forecast for 0JDI is $131.42M with a range of $111.00M to $147.56M. The previous quarter’s sales results were $325.00M. 0JDI beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 45.95% of the time in the same period. In the last calendar year 0JDI has Outperformed its overall industry.

0JDI Stock Forecast FAQ

What is GB:0JDI’s average 12-month price target, according to analysts?

Based on analyst ratings, Ionis Pharmaceuticals’s 12-month average price target is $58.69.

What is GB:0JDI’s upside potential, based on the analysts’ average price target?

Ionis Pharmaceuticals has 37.03% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Ionis Pharmaceuticals a Buy, Sell or Hold?

Ionis Pharmaceuticals has a conensus rating of Moderate Buy, which is based on 11 buy ratings, 4 hold ratings and 1 sell ratings.

What is Ionis Pharmaceuticals’s share price target?

The average share price target for Ionis Pharmaceuticals is $58.69. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $75.00 ,and the lowest forecast is $37.00. The average share price target represents 37.03% Increase from the current price of $42.83.

What do analysts say about Ionis Pharmaceuticals?

Ionis Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of Ionis Pharmaceuticals?

To buy shares of GB:0JDI, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Ionis Pharmaceuticals (0JDI) Share Forecast & Price Target

0JDI Analyst Ratings

0JDI Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

0JDI Analyst Recommendation Trends

0JDI Financial Forecast

0JDI Earnings Forecast

0JDI Sales Forecast

0JDI Stock Forecast FAQ

Get More with TipRanks Premium

Detailed List of Analyst Forecasts